AGMB (AgomAb Therapeutics NV) Other Long-Term Liabilities: $3.96 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $14.30
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Other Long-Term Liabilities?

AgomAb Therapeutics NV AGMB +1.96% 14 Other Long-Term Liabilities is $3.96 Mil as of Jun. 2026. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

AgomAb Therapeutics NV's other long-term liabilities for the quarter that ended in Jun. 2026 was $3.96 Mil.

AgomAb Therapeutics NV's quarterly other long-term liabilities declined from Sep. 2025 ($9.51 Mil) to Dec. 2025 ($3.76 Mil) but then increased from Dec. 2025 ($3.76 Mil) to Jun. 2026 ($3.96 Mil).

AgomAb Therapeutics NV's annual other long-term liabilities increased from Dec. 2023 ($8.18 Mil) to Dec. 2024 ($8.25 Mil) but then declined from Dec. 2024 ($8.25 Mil) to Dec. 2025 ($3.76 Mil).

AgomAb Therapeutics NV Other Long-Term Liabilities Related Terms

AgomAb Therapeutics NV Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Other Long-Term Liabilities Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
4.46 4.63 8.18 8.25 3.76

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial 8.18 8.25 9.51 3.76 3.96
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $3.96 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Other Long-Term Liabilities of $3.96 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Other Long-Term Liabilities too high?
AgomAb Therapeutics NV's current Other Long-Term Liabilities is $3.96 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Other Long-Term Liabilities compare to CRMD and RGNX?
AgomAb Therapeutics NV's Other Long-Term Liabilities of $3.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Other Long-Term Liabilities is $3.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Other Long-Term Liabilities of $3.96 Mil. The current Other Long-Term Liabilities is $3.96 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Other Long-Term Liabilities is $3.96 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.30
Price